NASDAQ: CASI | 中文 | Contact Us

Other Assets

For Greater China market:

CASI’s assets include a small portfolio of FDA-approved and FDA-pending ANDAs for generic products.

FDA-approved generic products for China market:

Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets – 50mg, Cilostazol tablets – 100mg, Ondansetron HCL tablets, and Tizanidine tablets

About Us

CASI Pharmaceuticals, Inc. is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. CASI has built a portfolio that includes approved and investigational assets. We conduct our commercial, clinical operations and R&D activities through our subsidiaries in China and branch office in Rockville, Maryland.

Learn More